The instrument relies on several key concepts defined either in the Act or in the instrument itself. An approved billing agent is a person (individual, partnership, corporation or other body) that has been approved under subsection 20AB(1) of the Act. The instrument does not restate the approval process itself but provides the mandatory criteria. An assignment is the legal mechanism under section 20A of the Act by which a medical practitioner directs that Medicare benefits be paid to the billing agent. This assignment is the core transaction: the billing agent collects the government benefit on behalf of the practitioner. The Chief Executive Medicare is the statutory officer responsible for administering the Medicare program; under the instrument, the Chief Executive must not approve an applicant unless the criteria are met. A prohibited person is defined by reference to Part 2D.6 of the Corporations Act 2001 , a person disqualified from managing a corporation. The instrument extends this disqualification to billing agents: a prohibited person cannot be an approved billing agent, and an entity cannot be approved if a person who manages it is prohibited. The concept of manages is broadly defined in section 6(2) to include directors, secretaries, decision-makers affecting substantial part of business, those who can significantly affect financial standing, or those who communicate instructions knowing the entity will act on them. This is a wide net. A trust account is required for all amounts received as a billing agent, and must generally be kept with a bank and separate from other accounts, unless compartmentalised. The instrument references the Corporations Regulations 2001 subregulation 7.8.02(2) for investment of trust money, imposing obligations akin to those on financial services licensees. The annual report required for renewal must be prepared by a qualified person , an auditor registered under the Corporations Act , and must include profit and loss, cash flow, balance sheet, and certification about trust account compliance with state laws. The 90-day payment requirement (undertaking 14) compels the billing agent to pay the assigning practitioner within 90 days after the Chief Executive Medicare makes payment to the agent. This is a key cash-flow rule. The patient statement requirement (undertaking 13) mandates that the billing agent provide each patient affected by an assignment with a statement listing item numbers, amounts charged, Medicare benefit, private health insurer payment, and patient out-of-pocket. The instrument also prohibits sub-appointment of another person to lodge claims unless that person is a registered organisation and pays amounts within 7 days. This restricts outsourcing of the claiming function. The approval is limited to one year maximum, requiring annual reapplication and renewal, which creates a recurring compliance cycle.

The instrument directly affects any person or entity that seeks to operate as a billing agent for Medicare assignments , that is, any business that intends to receive Medicare benefits on behalf of medical practitioners and then remit those amounts to the practitioners, usually after deducting agreed commissions or fees. This includes standalone billing companies, medical practice management firms, health insurance intermediaries, and potentially large hospital groups that process assignments for employed or visiting doctors. It also affects the medical practitioners who assign their Medicare benefits to these agents, because the instrument dictates payment timelines (90 days) and transparency requirements (patient statements) that practitioners must ensure their agents comply with. Practitioners are not directly regulated by this instrument but their commercial arrangements are shaped by it: the 90-day rule, trust account requirements, and commission restrictions limit the terms they can negotiate. Patients are affected indirectly: they are entitled to receive a detailed statement from the billing agent for each episode of care (undertaking 13), which includes not only what Medicare pays but also the private health insurer payment and any out-of-pocket amount. This imposes an administrative burden on the agent but gives the patient a clearer picture of the financial flows. Private health insurers are referenced in the definition of "private health insurer" (by reference to the Private Health Insurance Act 2007) and in the patient statement requirement (d) , the statement must include the amount payable by the private health insurer. So the instrument interacts with the private health insurance system, though insurers themselves are not regulated by it. The Chief Executive Medicare and the Department of Human Services are the administering bodies; they must process applications, receive annual reports, inspect books, and monitor compliance. Auditors and accountants are indirectly affected because the instrument requires annual reports prepared by a qualified person (registered auditor) and certification of trust account compliance. The broad definition of "manages" means that directors, officers, and even influential advisors of a billing agent entity may be personally affected if they become disqualified from managing corporations under Part 2D.6 of the Corporations Act , they could cause the entity to lose approval. The instrument also affects small businesses entering the market: the trust account requirement, annual audit, and one-year approval cycle create fixed compliance costs that may disproportionately affect smaller billing agents compared to larger established firms that can spread costs across more transactions. The prohibition on sub-appointing any person other than a registered organisation reduces flexibility: a small agent cannot outsource claim lodging to a specialist unless that specialist is a registered organisation, which may be a narrower category. Overall, the instrument creates a regulatory barrier to entry in the billing agent market, limiting competition and potentially increasing costs for medical practitioners who must use approved agents.

The instrument imposes duties primarily on the applicant (and later the approved billing agent) through the undertakings in Part 2 of the Schedule. These undertakings become conditions of approval under section 7. The key duties are:

Record keeping: The agent must keep a copy of each assignment and financial accounts relating to it for two years after the assignment (undertaking 8). This is a relatively short retention period compared to many business record requirements, but it aligns with the one-year approval cycle and likely limitation periods for disputes.

Inspection: The agent must allow the Chief Executive Medicare, an authorised departmental employee, or the Minister to inspect its books, records and accounts, and to take extracts and copies (undertaking 9). The undertaking expressly does not extend to non-consensual entry and search , that requires separate legislative authority. This is a limited right of inspection, not a warrantless search power.

Provision of information: On written request from an officer of the Chief Executive Medicare, the agent must give information about the conduct of its business or any particular transaction, without undue delay and in a convenient form (undertaking 10). This is a broad ongoing obligation.

Trust account maintenance: The agent must maintain the trust account for the approval period, pay all received amounts into it, operate it in accordance with the instrument's requirements, and invest money in compliance with Corporations Regulations subregulation 7.8.02(2) as if it were a financial services licensee (undertaking 11). This effectively imposes a fiduciary-like obligation on the use of client money, but without the full Australian Financial Services Licence regime. The investment rule is particularly onerous because it requires compliance with regulations designed for licensees, which may involve additional compliance infrastructure.

Restriction on sub-appointment: The agent cannot appoint another person to lodge claims on its behalf unless that person is a registered organisation and the appointment requires the organisation to pay all amounts received to the agent within 7 days (undertaking 12). This limits outsourcing flexibility and may force agents to perform claim lodgement in-house or use only registered organisations.

Patient statements: For each episode of service to a patient affected by an assignment, the agent must give the patient a statement itemising the item number, charged amount, Medicare benefit, private health insurer payment, and patient out-of-pocket (undertaking 13). This is a detailed disclosure duty. It does not specify timing , presumably it must be provided within a reasonable time after the service or after payment is received.

Payment to practitioner: The agent must pay the assigning practitioner the amount equal to the payment received from Medicare within 90 days after the Chief Executive Medicare makes the payment (undertaking 14). This is a strict payment timeline. The agent cannot hold the funds indefinitely; the 90-day window is the outer limit.

Earnings: The agent may apply interest from the trust account and charge commission only in accordance with an agreement with the medical practitioner (undertaking 15). This prevents the agent from unilaterally appropriating interest or charging fees not agreed.

Privacy: The agent must comply with the Privacy Act 1988 (undertaking 16). This imposes the Australian Privacy Principles on the handling of patients' personal information. Notably, this is an undertaking to comply with an existing statute; it does not create new privacy obligations but makes compliance a condition of approval. If the agent breaches the Privacy Act, that also breaches the approval conditions.

Change in circumstances: The agent must immediately notify the Chief Executive Medicare (not "without delay" but "immediately") if a trustee, liquidator or court-appointed agent is appointed, or if trust account information becomes inaccurate, or if the agent or a manager becomes disqualified under Corporations Act Part 2D.6 (undertaking 17). Within 14 days, the agent must notify of any change of name, address, or ownership. This imposes a strict and rapid reporting regime.

Statement of activity: Annually by 30 September following the anniversary of approval, the agent must give the Chief Executive a statement including numbers of claims, payments received from patients, episodes, days of hospitalisation, and total Medicare benefits paid to practitioners (undertaking 18). This is a significant reporting obligation that aggregates the agent's entire Medicare activity.

The rights of the agent are limited: it has the right to apply for approval and to be approved if criteria are met; it has the right to receive assigned Medicare benefits; and it has the right to earn commission and interest in accordance with agreements. But the instrument does not explicitly confer any rights; rather, it conditions the ability to operate. The Chief Executive Medicare has the right to inspect records, request information, and refuse or revoke approval based on these conditions.

The instrument itself does not create any monetary penalties or criminal offences. It is a legislative instrument made under the Health Insurance Act 1973, and enforcement would be found in the Act itself or in general law. The instrument's primary enforcement mechanism is the denial or revocation of approval. The Chief Executive Medicare must not approve an applicant if the criteria in Part 1 of the Schedule are not met (sections 1-6). For existing approved agents, section 7 makes approval conditional upon compliance with the undertakings given. Therefore, if an agent fails to comply with any undertaking (e.g. fails to pay a practitioner within 90 days, fails to provide a patient statement, fails to keep proper records, breaches privacy, does not provide the annual statement of activity), that failure would be a breach of a condition of approval. Under the Act (not detailed in this instrument), the Chief Executive Medicare would likely have power to revoke or suspend approval. The instrument does not specify a process for revocation or appeal, but such processes would be in the Act or administrative law. The undertaking to allow inspection and provide information (undertakings 9 and 10) suggests that non-cooperation could lead to non-compliance findings. There is no provision for a warning or cure period; the 90-day payment rule, for instance, is absolute. The annual approval renewal process (see section 5: approval for 1 year) means that the Chief Executive can effectively deny renewal if the agent fails to provide the required annual report (section 2) or updated information. The requirement for an annual activity statement (undertaking 18) must be given before 30 September each year. Failure to do so could trigger non-compliance. The trust account requirements are backed by the certification in the annual report (section 2(4)) that the trust account has been operated in accordance with state laws. If the audit reveals non-compliance, that likely leads to non-renewal or revocation. The instrument also contemplates that the agent must notify immediately if a disqualifying event occurs (undertaking 17). If the agent does not notify and continues to operate, that could be a breach of condition. The practical enforcement path is likely: the Chief Executive Medicare inspects records or receives a complaint; non-compliance is identified; the agent is given an opportunity to respond; approval is suspended or revoked. Given that approval is only for one year, the Chief Executive has a built-in review point at renewal. The instrument does not provide for fines, imprisonment, or civil penalties for breach of the conditions. However, the underlying Act may provide for offences, such as for making false statements in applications or knowingly providing false information. The instrument itself is silent on this. The only penalty mentioned is implicit: loss of approval, which effectively shuts down the agent's business in this field. This creates a strong incentive to comply, but also gives the Chief Executive significant discretionary power. The instrument does not require the Chief Executive to give reasons for refusal or revocation, though administrative law would likely imply such a duty. There is also no provision for internal review or merits review within the instrument, though such review may exist under the Act or the Administrative Appeals Tribunal Act. Overall, the enforcement mechanism is administrative and binary: you are either approved or not, and approval is conditional on continuous compliance.

This instrument interacts with several other pieces of Commonwealth legislation and with state law.

Health Insurance Act 1973: This is the parent Act. The instrument is made under subsections 20AB(5) and (6). The definitions in the Act of "approved billing agent" and "Medicare benefit" are incorporated by reference (section 6 note). The assignment mechanism under section 20A is the core transaction that the instrument regulates. The Act would also contain the general provisions regarding Medicare benefits, the functions of the Chief Executive Medicare, and any review or enforcement mechanisms. The instrument does not repeat those; it only provides the conditions and undertakings.

Corporations Act 2001: The instrument directly incorporates provisions of the Corporations Act. The definition of "prohibited person" in Part 1 of the Schedule refers to Part 2D.6 (disqualification from managing corporations). The definition of "Corporation" in section 6 uses the meaning in section 57A of the Corporations Act, which includes all incorporated bodies (including Aboriginal and Torres Strait Islander corporations) but not unincorporated bodies. The definition of "qualified person" for annual reports refers to an auditor registered under Part 9.2 of the Corporations Act. The trust account investment requirement (undertaking 11(d)) requires compliance with subregulation 7.8.02(2) of the Corporations Regulations 2001, which governs how financial services licensees must handle client money. By importing that requirement, the instrument effectively imposes a quasi-licensee standard on billing agents without requiring them to hold an Australian Financial Services Licence. This creates a regulatory overlap but potentially a higher standard than would otherwise apply.

Banking Act 1959: The definition of "bank" refers to an ADI under the Banking Act. This ensures trust accounts are held with prudentially regulated institutions.

Private Health Insurance Act 2007: The definition of "private health insurer" is taken from Schedule 1 of that Act. The patient statement requirement (undertaking 13(d)) requires disclosure of amounts payable by the private health insurer, integrating the billing agent's role with the private health insurance system.

Human Services (Medicare) Act 1973: The definition of Chief Executive Medicare references Part IIA of that Act.

Privacy Act 1988: Undertaking 16 requires compliance with the Privacy Act. This means that billing agents, which handle patients' personal and health information in the course of preparing statements and processing claims, must adhere to the Australian Privacy Principles. This imposes obligations regarding collection, use, disclosure, security, and access to information. The instrument makes privacy compliance a condition of approval, which is a strong enforcement mechanism. If an agent breaches the Privacy Act, it also breaches its approval conditions.

State and territory law: The trust account must be operated in accordance with the relevant laws of the State or States where the agent operates (see section 2(4)(b) and section 3(3)(b) re: compartmentalisation not being inconsistent with state law). The annual report must certify compliance with state trust account laws. This means billing agents may be subject to state legal profession or conveyancing trust account regulations, depending on their location. The instrument does not harmonise these requirements; it merely requires compliance with each relevant state's regime. This creates a potential burden for agents operating across state lines, as they must comply with multiple trust account laws.

Corporations Regulations 2001: As noted above, subregulation 7.8.02(2) governs investment of client money. The instrument applies this to billing agents, but excludes the flexibility that subregulations (3), (4), and (5) would normally provide. This means the agent must comply with a stricter version of the investment rules, potentially limiting the permitted investment options.

Subordinate legislation interaction: The instrument itself repealed and replaced the 2004 instruments. It does not reference other instruments such as the Health Insurance (Billing Agents) Guidelines etc. However, the note in the instrument suggests that earlier guidelines (1998, 2003, 2004) still condition approval: section 7 states that approval is conditional on compliance with undertakings given under Part 3 of those earlier Guidelines OR Part 1 of this instrument. This apparently grandfathers existing agents who gave undertakings under older guidelines , they must still comply with those older undertakings. This is a transitional interaction: new applicants will give undertakings under this instrument, but existing agents may still be bound by older forms. This creates complexity; an agent approved under a previous regime might have given different undertakings (e.g. regarding timing of payments or reporting). The instrument does not consolidate all undertakings; it simply says compliance with whichever set of undertakings given is a condition. This is a potential source of confusion for practitioners and agents.

The instrument as published does not include any amendments. It was made on 14 September 2017 by the then Minister for Health, Greg Hunt, and commenced the day after registration. It repealed the Health Insurance (Billing Agents - Conditions of Approval) Determination (No. 1) 2004 and the Health Insurance (Approval of Billing Agents) Guidelines (No. 1) 2004. Since its commencement, there may have been amendments by later instruments, but the text provided does not indicate any. The user should consult the Federal Register of Legislation for the current compilation. The instrument is a legislative instrument under the Legislation Act 2003, so it is subject to tabling, disallowance, and sunsetting. It has a sunsetting period (typically 10 years from registration), meaning it would lapse in 2027 unless remade. Therefore, this instrument may be superseded or repealed before that date. There is no amendment history within the instrument text itself. The instrument replaced older instruments from 2004, which themselves may have been amended earlier. The absence of amendment history in the source means we cannot detail any changes; we can only note the commencement and repeal.

The instrument text does not reference any court cases, appeals, or litigation history. As a subordinate instrument, it is unlikely to be the subject of direct litigation but it may have been considered in cases involving the Health Insurance Act. For example, the Administrative Appeals Tribunal may have reviewed decisions of the Chief Executive Medicare to refuse or revoke approval. There is no information in the instrument about any such cases. The user should search case law databases for "Health Insurance (Approved Billing Agents) Instrument 2017" or "approved billing agent" in the Federal Court and AAT. Given the instrument's technical nature and the narrow class of affected entities (billing agents), there may be little published litigation. The instrument does not provide a right of merits review; that would be under the Act or the Administrative Appeals Tribunal Act. Without source information, we cannot claim any specific litigation. We can note that the instrument's conditions could give rise to disputes about compliance, interpretation of "manages", or the scope of the 90-day rule, but no such cases are recorded in this instrument.

The instrument contains several features that may trap unwary applicants or approved agents.

1. The "prohibited person" net is wide. It applies not only to the applicant but also to any person who "manages" the applicant. The definition of "manages" in section 6(2) is extremely broad. It includes any director, secretary, or officeholder; any person who makes or participates in decisions that affect the whole or a substantial part of the business; any person who can significantly affect financial standing; or any person who communicates instructions or wishes to the entity knowing it is accustomed to act on them. This could catch passive investors, advisory board members, or senior employees who are not formal directors. If such a person becomes disqualified from managing corporations under Part 2D.6 of the Corporations Act, the entity's approval is at risk , and must be immediately notified under undertaking 17(1)(c).

2. Trust account compartmentalisation is a limited exception. Section 3(3) allows the trust account not to be a separate account if it is "compartmentalised or maintained in such a way as to keep amounts received by the applicant as a billing agent separate from all other amounts" and if it is not inconsistent with Commonwealth or state law. This is not a free pass; the compartmentalisation must be genuine and must comply with law. In practice, many banks may not offer suitable compartmentalised accounts, and state trust account legislation may require a separate account. The exception may be unworkable.

3. The 90-day payment rule is absolute. Undertaking 14 requires payment to the assigning practitioner "within 90 days after the Chief Executive Medicare makes the payment." The clock starts from the date Medicare pays the agent, not from when the agent receives it (though that is likely the same). There is no grace period, no extension for disputes, and no allowance for administrative delays. If the agent holds the funds for 91 days, it is in breach of a condition of approval. This is a strict liability type obligation.

4. The annual activity statement deadline is inflexible. Undertaking 18 requires the statement to be given "on or before 30 September next following the anniversary of the day of approval." Note: the anniversary date, not the end of the financial year. This could catch agents who think it aligns with the June 30 year-end. They must calculate the exact date of approval each year and deliver the statement by 30 September after that anniversary. If approval was granted on, say, 15 November 2017, the first statement is due by 30 September 2018, covering activity from 15 November 2017 to 15 November 2018? The wording is ambiguous: "the number of claims it has made for Medicare benefits" during what period? The instrument does not specify the reporting period, leaving it open to interpretation. This ambiguity creates compliance risk.

5. The undertaking for "changes in circumstances" requires immediate notification. Undertaking 17(1) says "immediately" for certain events (appointment of trustee, liquidator, court-appointed agent; change affecting trust account accuracy; disqualification of manager). "Immediately" is a very high standard; if an agent learns of a disqualification at 5pm on a Friday, they might be expected to notify by email or phone that day. Failure to do so could be a breach.

6. Sub-appointment is heavily restricted. Undertaking 12 prohibits appointing another person to lodge claims unless that person is a "registered organisation" (undefined in the instrument, but presumably refers to organisations registered under the Health Insurance Act for the purposes of claiming , possibly hospitals or medical practices). And even then, the registered organisation must pay all amounts received to the agent within 7 days. This prevents the agent from outsourcing the claiming function to a third-party specialist that is not a registered organisation, even if that specialist could do the job more efficiently. This is a barrier to using modern clearinghouses or billing service providers.

7. The trust account investment rule is stricter than for many professionals. Undertaking 11(d) requires compliance with Corporations Regulations subregulation 7.8.02(2), as if it were not subject to subregulations (3), (4) and (5). Those subregulations normally allow licensees to deposit client money into certain accounts or to invest in specified products. By excluding those exceptions, the instrument imposes the base rule without the usual flexibilities. This may limit the agent's ability to earn interest on trust funds or may require additional compliance steps.

8. The annual report requirement for renewal may be costly. Section 2 of Part 1 of the Schedule requires a full audited financial report (profit and loss, cash flow, balance sheet) for the preceding financial year, prepared by an independent registered auditor. This is a significant annual cost, especially for a small billing agent with low transaction volumes. The cost may exceed the profits from the agency business, effectively making small-scale operations uneconomical.

9. The patient statement requirement imposes per-episode administrative costs. Undertaking 13 requires a statement for each episode for each patient. For a billing agent processing hundreds of thousands of claims, generating and delivering these statements (even electronically) is a non-trivial operational cost. The instrument does not specify that the statement can be provided electronically or as part of a batch, potentially increasing postage and printing costs. Failure to provide a statement for any episode is a breach.

10. Grandfathered older undertakings may still apply. Section 7 conditions approval on compliance with undertakings given under earlier guidelines (1998, 2003, 2004) or Part 1 of this instrument. An agent approved under the old regime who gave undertakings under Part 3 of the 1998 Guidelines must continue to comply with those old undertakings until they are changed. The instrument does not provide a mechanism to replace old undertakings with the new ones. This could lead to different obligations for different agents, creating an uneven playing field and confusion.

Compliance with this instrument requires a systematic approach across application, ongoing operations, and renewal.

Initial application. Before applying, ensure that the applicant is not a prohibited person and that no person who manages the applicant is prohibited. For corporations, provide the ACN or certificate of incorporation (section 4). Establish a trust account with a bank (an ADI) that meets the requirements of section 3: either a separate account or a properly compartmentalised account. Provide the Chief Executive Medicare with the account name, number, and bank details (including BSB). Prepare the set of undertakings in the form approved by the Chief Executive Medicare (see section 6). These undertakings are prescribed in Part 2 of the Schedule; the applicant must sign them and submit them with the application. Approval is for one year only, so the applicant must anticipate renewal.

Ongoing trust account management. Pay all amounts received from Medicare assignments into the trust account. Operate the account in accordance with relevant state laws. If compartmentalisation is used, ensure it is genuinely separate and that it is not inconsistent with applicable law. Invest trust money only in accordance with the strict version of Corporations Regulations subregulation 7.8.02(2) (excluding the exceptions). Do not use trust money for the agent's own operating expenses. Only apply interest or charge commission pursuant to written agreements with the relevant medical practitioners.

Record keeping. For each assignment, retain a copy of the assignment document and the associated financial accounts for two years from the date of the assignment. This includes records of payments received from Medicare and payments made to practitioners. The two-year retention period starts from the assignment date, not from the end of the financial year.

Patient statements. After each episode of service involving an assigned practitioner, provide the patient with a statement that includes the item number, the amount charged, the Medicare benefit payable, the private health insurer payment (if applicable), and the patient's out-of-pocket amount. The instrument does not specify the timing; to minimise risk, provide the statement within a reasonable time after the service, and certainly before seeking payment from the patient.

Payment to practitioners. Ensure that the practitioner receives the amount equal to the Medicare benefit paid to the agent within 90 days of the Chief Executive Medicare making that payment. Set up systems to track payment dates and automatically remit funds. The 90-day period is from Medicare's payment date, not from when the agent's bank clears the funds; allow a buffer.

Sub-appointment. Do not appoint any third party to lodge claims on the agent's behalf unless that third party is a registered organisation and the agreement requires that organisation to pay all amounts received to the agent within 7 days of receipt. If the agent directly lodges claims, no issue; but if outsourcing, vet the third party carefully.

Compliance with Privacy Act. Implement policies and procedures to comply with the Australian Privacy Principles. This includes obtaining patient consent for collection of health information, ensuring secure storage, providing access, and handling complaints. Since the billing agent will handle patient details from the medical practitioner's assignment, ensure that the practitioner has obtained consent to share information with the agent.

Reporting to Chief Executive Medicare. Submit the annual activity statement (undertaking 18) on or before 30 September following the anniversary of approval. The statement must include: number of claims made for Medicare benefits; number of claims submitted to patients and statements given; total payments received from patients; number of episodes included in assigned rights processed; number of days of hospitalisation included; and total Medicare benefits paid to assigning medical practitioners. Ensure the reporting system captures these metrics for the period from the approval anniversary to the next anniversary (or as required).

Notification of changes. Monitor for changes in circumstances. If a trustee, liquidator, or court-appointed agent is appointed over the applicant's affairs, notify the Chief Executive Medicare immediately. Also, notify immediately if there is any change affecting the accuracy of the trust account information previously provided, or if the applicant or a manager becomes disqualified from managing corporations. Within 14 days of any change of name, address, or ownership, notify the Chief Executive Medicare. Treat "immediately" as the same day or next business day.

Annual renewal. Before the approval expires (maximum one year from date of approval), apply for renewal. For renewal applicants (those whose approval has expired or is about to expire), the Chief Executive Medicare must not approve unless the applicant has given a copy of an annual report for the preceding financial year, prepared by a qualified person (registered auditor). The report must include profit and loss, cash flow, and balance sheet, and must certify that the trust account was operated in accordance with state laws. If the annual report is not available at the time of application, the applicant must undertake to provide it before 30 September in the financial year of application. Plan the renewal timeline: start the audit early to have the report ready.

Staff training and oversight. Ensure that employees are aware of the undertakings, especially record keeping, patient statement generation, and payment timelines. The undertaking in section 7 requires the applicant (individual or corporation) to take all reasonable steps to ensure compliance by employees, managers, and partners. Document these steps.

Potential use of earlier undertakings. If the applicant was approved under a previous instrument (1998, 2003, 2004 Guidelines), note that the conditions of approval include compliance with the undertakings given under that earlier regime. Do not assume that the new instrument replaces those obligations. Seek legal advice on whether to convert to the new undertakings.

By following these steps, a billing agent can maintain its approved status and avoid loss of approval, which would terminate its ability to operate in the Medicare assignment market. The compliance burden is substantial, particularly for small agents, but the instrument leaves little room for discretion.